Table 1

Baseline characteristics, all patients

All patients (N = 521)


Age


Years, median (range)

66.3 (39-86)


≥ 70 years, n (%)

188 (36.1)


Gender, n (%) male

363 (69.7)


Origin, n (%) Caucasian

514 (98.7)


Weight, kg [mean (SD)]

74.9 (14.45)


Smoking status, n (%)


Current smoker

139 (26.7)


Ex-smoker

243 (46.6)


Never smoked

138 (26.5)


Missing data

1 ( 0.2)


Histology, n (%)


Non-squamous cell carcinoma

444 (85.2)


Squamous cell carcinoma a

77 (14.8)


Disease stage at study entry, n (%)


Stage IIIa

35 ( 6.7)


Stage IIIb

103 (19.8)


Stage IV

383 (73.5)


All patients (N = 521)


Karnofsky Index (KI), n (%)


KI ≥ 80%

323 (62.0)


KI 70%

134 (25.7)


KI 60%

45 ( 8.6)


KI 50%

18 ( 3.5)


Missing data

1 ( 0.2)


Type of previous first-line chemotherapy


Platinum-based combinations, n (%)

450 (86.4)


Platinum-free combinations, n (%)

12 ( 2.3)


Single-agent, n (%)

59 (11.3)


Most frequent agents used (at least 10% of patients), n (%)b


Carboplatin

327 (62.8)


Cisplatin

135 (25.9)


Vinorelbine

162 (31.1)


Gemcitabine

159 (30.5)


Paclitaxel

131 (25.1)


Duration of previous first-line chemotherapy, months [median (range)]

3.5 (0-32)


Time elapsed since previous first-line chemotherapy, months [median (range)]

3.9 (0-74)


Patients [n (%)] who started pemetrexed


Immediately after end of first-line treatmentc

82 (15.7)


Within 3 months after end of first-line treatmentd

132 (25.3)


More than 3 months after end of first-line treatmente

302 (58.0)


Missing data

5 (1.0)


N = total number of patients, n = number of patients, SD standard deviation

a) The study started in 2007, before the label change in April 2008 which restricted the use of pemetrexed to patients with non-squamous cell carcinoma

b) Multiple nominations possible

c) First dose of pemetrexed given ≤ 28 days after the last dose of first-line therapy

d) First dose of pemetrexed dose given > 28 days but ≤ 3 months after the last dose of first-lintherapy

e) First dose of pemetrexed dose given > 3 months after the last dose of first-line therapy

Schuette et al. BMC Cancer 2012 12:14   doi:10.1186/1471-2407-12-14

Open Data